Intervacc awarded funding from Vinnova for further development of vaccine against Staphylococcus aureus infections
Stockholm 25 March 2020 - Intervacc AB (publ) will continue the development of its new vaccine against Staphylococcus aureus infections that cause mastitis in dairy cows. The project will be co-financed by Intervacc and Vinnova within the framework of innovation projects at small and medium-sized companies - Autumn 2019. Financing covers a part of the preclinical phase of the development program with a budget of SEK 3.9 million. Vinnova has motivated its decision, which was made in face of strong competition from other applications, with the following comments: · The project results